None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Only those who give written informed consent for participation in trial will be included in the study. 2. Only those women who are permanent resident of the village and willing to stay in the study area for the next two years will be included
Exclusion criteria
Exclusion criteria: 1. The eligible couples wherein either of the partner have adopted any permanent method of contraception will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in Pre-conception health among women from eligible couple as ascertained by the proportion of women who would enter pregnancy in good health without undernutrition, anaemia and depression.Timepoint: Five time points every six monthly starting after six months of intervention with endline conducted at 36 months. Beyond these a baseline assessment will be conducted. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes include improved maternal & child health outcomes, such as reductions in stillbirth rate, neonatal mortality rate (NMR), infant mortality rate (IMR), & severe maternal morbidities (e.g., pre-eclampsia, gestational diabetes, maternal depression, hemorrhage, & abortion). Other outcomes include lower rates of low birth weight, stunting at age one, delayed first pregnancies, longer birth intervals, & more planned pregnancies.Timepoint: A cohort of potential beneficiaries will be followed from conception through pregnancy outcomes & until the child turns one year old for live births. ;The secondary outcomes include examining the factors that facilitate or hinder the implementation & use of the PCC package, assessing the feasibility of the intervention using the RE-AIM framework, & estimating the unit cost of delivering community-based PCC services accounting for direct, indirect, & opportunity costs, aiding future policy advocacy for the PCC package. In addition, sub-clinical parameters related to anemia, including serum ferritin & vitamin B12 levels, will be measured.Timepoint: Implementation outcomes & cost of implementation will be estimated through endline survey & barrier analysis at 36 months Biochemical profiling will be conducted on a subsample of 1,920 individuals (640 each) at baseline, an interim survey 3 at 18 months, & endline. | — |
Countries
India
Contacts
Mahatma Gandhi Institute of Medical Sciences, Sevagram